294 related articles for article (PubMed ID: 9811517)
1. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.
Savage M; Torres J; Franks L; Masecar B; Hotta J
Biologicals; 1998 Jun; 26(2):119-24. PubMed ID: 9811517
[TBL] [Abstract][Full Text] [Related]
2. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
3. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
4. Determination of moisture content of lyophilized allergen vaccines by NIR spectroscopy.
Zheng Y; Lai X; Bruun SW; Ipsen H; Larsen JN; Løwenstein H; Søndergaard I; Jacobsen S
J Pharm Biomed Anal; 2008 Feb; 46(3):592-6. PubMed ID: 18162356
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
Roberts PL; Hart H
Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
[TBL] [Abstract][Full Text] [Related]
6. In-line multipoint near-infrared spectroscopy for moisture content quantification during freeze-drying.
Kauppinen A; Toiviainen M; Korhonen O; Aaltonen J; Järvinen K; Paaso J; Juuti M; Ketolainen J
Anal Chem; 2013 Feb; 85(4):2377-84. PubMed ID: 23351045
[TBL] [Abstract][Full Text] [Related]
7. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
9. Validation of a multipoint near-infrared spectroscopy method for in-line moisture content analysis during freeze-drying.
Kauppinen A; Toiviainen M; Lehtonen M; Järvinen K; Paaso J; Juuti M; Ketolainen J
J Pharm Biomed Anal; 2014 Jul; 95():229-37. PubMed ID: 24699368
[TBL] [Abstract][Full Text] [Related]
10. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
11. Strategies for multivariate modeling of moisture content in freeze-dried mannitol-containing products by near-infrared spectroscopy.
Yip WL; Gausemel I; Sande SA; Dyrstad K
J Pharm Biomed Anal; 2012 Nov; 70():202-11. PubMed ID: 22824636
[TBL] [Abstract][Full Text] [Related]
12. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
Horowitz B; Prince AM
Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
[TBL] [Abstract][Full Text] [Related]
13. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
Smith MP; Rice KM; Savidge GF
Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
[No Abstract] [Full Text] [Related]
14. Applying spectral peak area analysis in near-infrared spectroscopy moisture assays.
Brülls M; Folestad S; Sparén A; Rasmuson A; Salomonsson J
J Pharm Biomed Anal; 2007 May; 44(1):127-36. PubMed ID: 17391888
[TBL] [Abstract][Full Text] [Related]
15. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
[TBL] [Abstract][Full Text] [Related]
16. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products.
Unger U; Poelsler G; Modrof J; Kreil TR
Transfusion; 2009 Sep; 49(9):1924-30. PubMed ID: 19453977
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
18. Measurement of final container residual moisture in freeze-dried biological products.
May JC; Wheeler RM; Etz N; Del Grosso A
Dev Biol Stand; 1992; 74():153-64. PubMed ID: 1592165
[TBL] [Abstract][Full Text] [Related]
19. Determination of residual moisture in lyophilized protein pharmaceuticals using a rapid and non-invasive method: near infrared spectroscopy.
Lin TP; Hsu CC
PDA J Pharm Sci Technol; 2002; 56(4):196-205. PubMed ID: 12181804
[TBL] [Abstract][Full Text] [Related]
20. The effect of residual moisture in lyophilized smallpox vaccine on its stability at different temperatures.
Sparkes JD; Fenje P
Bull World Health Organ; 1972; 46(6):729-34. PubMed ID: 4538534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
